Ultragef 250mg Tablet

Ultragef 250mg Tablet is an anticancer medicine that belongs to the class of tyrosine kinase inhibitors and contains the active ingredient gefitinib. It is prescribed for the treatment of non-small cell lung cancer (NSCLC). NSCLC is a type of lung cancer in which abnormal cells grow and multiply uncontrollably within the lung tissues. This medicine is indicated for patients whose NSCLC has spread to other parts of the body, who have specific epidermal growth factor receptor (EGFR) gene mutations, and who have not previously received treatment for their cancer. Certain formulations of Ultragef 250mg Tablet may contain lactose as an inactive ingredient. People with lactose intolerance may have difficulty digesting lactose, a natural sugar found in milk and dairy products, which can lead to symptoms such as bloating and abdominal pain. Inform your doctor if you are lactose intolerant before starting this medication. Tell your healthcare provider if you have kidney or liver disease, vision disorders, lung problems, or if you are taking blood-thinning medicines such as warfarin. Your doctor may recommend regular blood tests during treatment to monitor your health and reduce the risk of complications. Avoid drinking alcohol while taking Ultragef 250mg Tablet, as it may increase the risk of dizziness. Consult your doctor before using this medicine if you are pregnant or planning to become pregnant. This medication is not recommended during pregnancy because it may harm the developing fetus. Your healthcare provider will perform a pregnancy test before starting treatment and advise you to use effective contraception during therapy and for at least two weeks after the final dose. Breastfeeding should also be avoided while taking Ultragef 250mg Tablet, as it is not known whether gefitinib passes into breast milk.

Ultragef 250mg Tablet is used to treat Non-small cell lung cancer.

It is an anilinoquinazoline derivative that interacts with a kinase inhibitor that inhibits an abnormal protein called the epidermal growth factor receptor (EGFR). This helps to slow or stop the growth of cancer cells and reduce the size of tumors in patients with NSCLC.

The medicine will be prescribed to you by a healthcare professional in a hospital setting. Gefitinib is available as a tablet to be taken with or without food, as directed by your healthcare provider. The usual recommended dosage is 250 mg tablet once daily. Avoid crushing, opening, or dissolving the tablet, swallow it whole with a glass of water. Take the Ultragef 250mg tablet at the same time every day.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common diarrhea nausea vomiting loss of appetite weakness red or sore mouth increased liver enzymes itchy or cracked skin dry mouth red or itchy eyes nail problems hair loss fever blood in the urine and burning sensation while urinating

Ultragef 250mg is not recommended for children and adolescents below 18. It is advisable to monitor your blood pressure regularly during this treatment. Avoid high-fiber foods and drink lots of fluids if you have severe diarrhea. Antacids should not be used two hours before or one hour after taking this tablet. Avoid driving and operating heavy machinery if you feel tired or weak during this treatment.